164 related articles for article (PubMed ID: 23686431)
21. WIF1 was downregulated in cervical cancer due to promoter methylation.
Wang Y; Yuan S; Ma J; Liu H; Huang L; Zhang F; Wang X
Acta Biochim Pol; 2023 Jun; 70(2):419-423. PubMed ID: 37306343
[TBL] [Abstract][Full Text] [Related]
22. Promoter hypermethylation of Wnt inhibitory factor-1 in patients with lung cancer: A systematic meta-analysis.
Zheng Y; Li X; Jiang Y; Xu Y; Song B; Zhou Q; Liang X; Yang X
Medicine (Baltimore); 2016 Dec; 95(49):e5433. PubMed ID: 27930522
[TBL] [Abstract][Full Text] [Related]
23. Aberrant expression of the sFRP and WIF1 genes in invasive non-functioning pituitary adenomas.
Song W; Qian L; Jing G; Jie F; Xiaosong S; Chunhui L; Yangfang L; Guilin L; Gao H; Yazhuo Z
Mol Cell Endocrinol; 2018 Oct; 474():168-175. PubMed ID: 29555596
[TBL] [Abstract][Full Text] [Related]
24. Clinical significance of aberrant methylation of prostaglandin E receptor 2 (PTGER2) in nonsmall cell lung cancer: association with prognosis, PTGER2 expression, and epidermal growth factor receptor mutation.
Tian L; Suzuki M; Nakajima T; Kubo R; Sekine Y; Shibuya K; Hiroshima K; Nakatani Y; Fujisawa T; Yoshino I;
Cancer; 2008 Sep; 113(6):1396-403. PubMed ID: 18666211
[TBL] [Abstract][Full Text] [Related]
25. Suppression of Wnt signaling by the miR-29 family is mediated by demethylation of WIF-1 in non-small-cell lung cancer.
Tan M; Wu J; Cai Y
Biochem Biophys Res Commun; 2013 Sep; 438(4):673-9. PubMed ID: 23939044
[TBL] [Abstract][Full Text] [Related]
26. Prognostic relevance of Wnt-inhibitory factor-1 (WIF1) and Dickkopf-3 (DKK3) promoter methylation in human breast cancer.
Veeck J; Wild PJ; Fuchs T; Schüffler PJ; Hartmann A; Knüchel R; Dahl E
BMC Cancer; 2009 Jul; 9():217. PubMed ID: 19570204
[TBL] [Abstract][Full Text] [Related]
27. c‑Jun suppresses the expression of WNT inhibitory factor 1 through transcriptional regulation and interaction with DNA methyltransferase 1 in gallbladder cancer.
Lin B; Hong H; Jiang X; Li C; Zhu S; Tang N; Wang X; She F; Chen Y
Mol Med Rep; 2018 Jun; 17(6):8180-8188. PubMed ID: 29693707
[TBL] [Abstract][Full Text] [Related]
28. Promoter methylation of Wnt antagonist DKK1 gene and prognostic value in Korean patients with non-small cell lung cancers.
Na Y; Lee SM; Kim DS; Park JY
Cancer Biomark; 2012; 12(2):73-9. PubMed ID: 23396252
[TBL] [Abstract][Full Text] [Related]
29. Epigenetic inactivation of Homeobox A5 gene in nonsmall cell lung cancer and its relationship with clinicopathological features.
Kim DS; Kim MJ; Lee JY; Lee SM; Choi JY; Yoon GS; Na YK; Hong HS; Kim SG; Choi JE; Lee SY; Park JY
Mol Carcinog; 2009 Dec; 48(12):1109-15. PubMed ID: 19554572
[TBL] [Abstract][Full Text] [Related]
30. Methylation analysis for multiple gene promoters in non-small cell lung cancers in high indoor air pollution region in China.
Huang X; Wu C; Fu Y; Guo L; Kong X; Cai H
Bull Cancer; 2018 Sep; 105(9):746-754. PubMed ID: 30126609
[TBL] [Abstract][Full Text] [Related]
31. The effect of EBV on WIF1, NLK, and APC gene methylation and expression in gastric carcinoma and nasopharyngeal cancer.
Zhao Z; Liu W; Liu J; Wang J; Luo B
J Med Virol; 2017 Oct; 89(10):1844-1851. PubMed ID: 28543390
[TBL] [Abstract][Full Text] [Related]
32. Genome-wide DNA methylation analyses in lung adenocarcinomas: Association with EGFR, KRAS and TP53 mutation status, gene expression and prognosis.
Bjaanæs MM; Fleischer T; Halvorsen AR; Daunay A; Busato F; Solberg S; Jørgensen L; Kure E; Edvardsen H; Børresen-Dale AL; Brustugun OT; Tost J; Kristensen V; Helland Å
Mol Oncol; 2016 Feb; 10(2):330-43. PubMed ID: 26601720
[TBL] [Abstract][Full Text] [Related]
33. Genetic and epigenetic alterations of the LKB1 gene and their associations with mutations in TP53 and EGFR pathway genes in Korean non-small cell lung cancers.
Lee SM; Choi JE; Na YK; Lee EJ; Lee WK; Choi YY; Yoon GS; Jeon HS; Kim DS; Park JY
Lung Cancer; 2013 Aug; 81(2):194-9. PubMed ID: 23664447
[TBL] [Abstract][Full Text] [Related]
34. Epigenetic inactivation of the RAS-effector gene RASSF2 in lung cancers.
Kaira K; Sunaga N; Tomizawa Y; Yanagitani N; Ishizuka T; Saito R; Nakajima T; Mori M
Int J Oncol; 2007 Jul; 31(1):169-73. PubMed ID: 17549418
[TBL] [Abstract][Full Text] [Related]
35. WIF1, a Wnt pathway inhibitor, regulates SKP2 and c-myc expression leading to G1 arrest and growth inhibition of human invasive urinary bladder cancer cells.
Tang Y; Simoneau AR; Liao WX; Yi G; Hope C; Liu F; Li S; Xie J; Holcombe RF; Jurnak FA; Mercola D; Hoang BH; Zi X
Mol Cancer Ther; 2009 Feb; 8(2):458-68. PubMed ID: 19174556
[TBL] [Abstract][Full Text] [Related]
36. Diagnostic role of Wnt pathway gene promoter methylation in non small cell lung cancer.
Liu S; Chen X; Chen R; Wang J; Zhu G; Jiang J; Wang H; Duan S; Huang J
Oncotarget; 2017 May; 8(22):36354-36367. PubMed ID: 28422739
[TBL] [Abstract][Full Text] [Related]
37. Down-regulation of PAX6 by promoter methylation is associated with poor prognosis in non small cell lung cancer.
Zhang X; Yang X; Wang J; Liang T; Gu Y; Yang D
Int J Clin Exp Pathol; 2015; 8(9):11452-7. PubMed ID: 26617874
[TBL] [Abstract][Full Text] [Related]
38. DNA Methylation status of Wnt antagonist SFRP5 can predict the response to the EGFR-tyrosine kinase inhibitor therapy in non-small cell lung cancer.
Zhu J; Wang Y; Duan J; Bai H; Wang Z; Wei L; Zhao J; Zhuo M; Wang S; Yang L; An T; Wu M; Wang J
J Exp Clin Cancer Res; 2012 Sep; 31(1):80. PubMed ID: 23009178
[TBL] [Abstract][Full Text] [Related]
39. Wnt inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancer.
Mazieres J; He B; You L; Xu Z; Lee AY; Mikami I; Reguart N; Rosell R; McCormick F; Jablons DM
Cancer Res; 2004 Jul; 64(14):4717-20. PubMed ID: 15256437
[TBL] [Abstract][Full Text] [Related]
40. miR-181c contributes to cisplatin resistance in non-small cell lung cancer cells by targeting Wnt inhibition factor 1.
Zhang H; Hu B; Wang Z; Zhang F; Wei H; Li L
Cancer Chemother Pharmacol; 2017 Nov; 80(5):973-984. PubMed ID: 28956120
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]